Conveners
Session 1 - Radiopharmaceutical Chemistry (radiodiagnostics, radiotherapy, theragnostics)
- Cathy Cutler (University of Missouri, USA)
Prof.
Jean-François chatal
(GIP ARRONAX, France)
17/09/2012, 10:00
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Invited Lecture
For the last two decades a technological revolution has deeply changed the field of application of nuclear medicine. Today PET/CT imaging using 18F-Fluorodeoxyglucose (FDG) is considered as the standard imaging technique in oncology for tumor staging, detection of recurrence and early evaluation of response to treatment. PET/MRI could shortly become the standard imaging technique in neurology....
Prof.
Suresh Srivastava
(Brookhaven National Laboratory, USA)
17/09/2012, 10:30
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Invited Lecture
A major advantage of radionuclides is that they emit radiation of different radiobiological effectiveness and range of action. This offers the possibility of choosing a nuclide the physical and nuclear characteristics of which are matched with a particular tumor type, or the disease under treatment. This presentation introduces a relatively novel paradigm that involves specific individual...
Prof.
Roger Alberto
(University of Zurich, Switzerland)
17/09/2012, 11:00
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Invited Lecture
Imaging and visualization of molecular events on the cellular and subcellular level requires the design and the syntheses of highly specific compounds which have to to accumulate at desired target sites but should be rapidly cleared from non-targeted organs. Visualization must take place at the living intact subject and the patient.[1] This makes radiolabeled compounds a priority modality for...
Prof.
Frank Roesch
(University of Mainz, Germany)
17/09/2012, 11:20
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Invited Lecture
Introduction: Radionuclide generator systems continue to play a key role in providing both diagnostic and therapeutic radionuclides for various applications in nuclear medicine, oncology and interventional cardiology. In parallel to the well established 99Mo/99mTc generator used for SPECT imaging, new generators for PET/CT imaging attract attention. In particular the...
Dr
Marco Chinol
(European Institute of Oncology, Italy), Dr
Stefano Papi
(European Institute of Oncology, Italy)
17/09/2012, 11:40
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Invited Lecture
Somatostatin analogues designed to target tumor cells over-expressing somatostatin receptors have been radiolabelled with 90Y- and 177Lu for peptide receptor radionuclide therapy (PRRT). Clinical trials evidenced large patient variability as regards tumor and organs uptake, thus sustaining the need of tailored dosimetry, for a treatment course with improved safety and efficacy. However,...
Dr
Stanislav Pavelka
(Department of Radiometry, Institute of Physiology, v.v.i., Academy of Sciences of the Czech Republic, Prague; and Institute of Biochemistry, Masaryk University, Brno, Czech Republic)
17/09/2012, 12:00
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Oral Communications
Pavelka S.1,2, Macek Jílková Z.3 and Kopecký J.3
1Department of Radiometry, Institute of Physiology, v.v.i., Academy of Sciences of the Czech Republic, Prague; 2Institute of Biochemistry, Masaryk University, Brno; and 3Department of Adipose Tissue Biology, Institute of Physiology, v.v.i., ASCR, Prague, Czech Republic
The metabolism of thyroid hormones (TH) in white adipose tissue (WAT)...
Dr
Sandrine Huclier-Markai
(Laboratoire Subatech, UMR 6457, Ecole des Mines de Nantes /CNRS/IN2P3 / Université de Nantes, 4 Rue A. Kastler, BP 20722, F-44307 Nantes Cedex 3, France.)
17/09/2012, 12:15
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Oral Communications
The use of radionuclides as potential therapeutic radiopharmaceuticals is increasingly investigated. Scandium isotopes (44Sc, 47Sc) become more easily available and their properties are convenient for either PET imaging or radiotherapy. Notably, the half-life of 3.97 h of 44Sc and its high positron branching (94%) lead us to consider this isotope for application in TEP radiopharmaceuticals....
Mr
Seweryn Krajewski
(Institute of Nuclear Chemistry and Technology, Dorodna Street 16, 01312 Warsaw, Poland)
17/09/2012, 12:30
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Oral Communications
Recently, great effort is put in development of personalised treatment, including precise diagnoses and therapy using the same molecular targeting vectors. Scandium radioisotopes give opportunity to obtain PET/CT images using 44Sc (τ1/2 = 3.92 h) and 43Sc (τ1/2 = 3.89 h) and to treat tumours with a low energy β--particles using 47Sc (τ1/2 = 3.35 d). The aim of our work was to developed simple...
Ms
Edyta Leszczuk
(Institute of Nuclear Chemistry and Technology, Poland)
17/09/2012, 12:45
Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnostics
Oral Communications
There are only a few a-particle emitting radionuclides that have properties suitable for developing therapeutic radiopharmaceuticals. Unfortunately, all available a-emitters have serious disadvantages: 211At forms weak bond with carbon atoms in the biomolecule and in the case of 212Bi, 213Bi and 226Th short half-life often limits the application of these nuclides. However, the short half-life...
